Greetings and welcome to Rigel Pharmaceutical's Financial Conference Call for the Third Quarter 2024. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce our first speaker, Ray Furey, Rigel's Executive Vice President, General Counsel, and Corporate Secretary.

Welcome to our third quarter 2024 financial results and business update conference call. The financial press release for the third quarter 2024 was issued a short while ago and can be viewed along with the slides for this presentation in the news and events section of our investor relations site on Rigel.com. As a reminder, during today's call, we may make forward-looking statements regarding our financial outlook and our plans and timing for regulatory and product development. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent annual report on form 10-K for the year ended December 31st, 2023, and subsequent filings with the SEC including our Q3 quarterly report on form 10-Q filed with the SEC. Any forward-looking statements are made only as of today's date and we undertake no obligation to update these forward-looking statements to reflect subsequent events or circumstances. At this time, I'd like to turn the call over to our President and Chief Executive Officer, Raul Rodriguez.

Thank you, Ray, and thank you, everyone, for joining today. Also with me today are Dave Santos, our Chief Commercial Officer; Lisa Rojkjaer, our Chief Medical Officer; and Dean Schorno, our Chief Financial Officer. I'll begin on Slide 4 with an overview of Rigel's business and our third quarter results. In the first three quarters of the year, we made significant progress in our strategy to grow our hematology and oncology business. Our corporate strategy is focused on three main objectives; one, expanding our commercial portfolio and increasing product sales. Two, advancing and growing our pipeline through strategic collaborations and importantly, internal pipeline development, and three, maintaining financial discipline. I will now summarize each of these. Firstly, in the third quarter, we generated strong growth across our commercial portfolio with a total net sales of 38.9 million, which was up 44% compared to the third quarter of 2023. This robust revenue growth was driven by the addition of GAVRETO, which generated 7.1 million in net product sales for its first full quarter with Rigel, as we transitioned the majority of patients and prescribers into our network. In addition, we saw continued year-over-year growth for TAVALISSE and REZLIDHIA, with both achieving another record quarter for bottles shipped to patients and clinics. We continue to expand our product presence outside the US this quarter, with a new Kissei agreement to develop and commercialize REZLIDHIA in Japan, the Republic of Korea, and Taiwan. This agreement included a 10 million upfront payment that we received in Q3 and the potential for up to 152 million in future development, regulatory, and commercial milestone payments. Secondly, regarding our goal to grow our pipeline, we continue to advance the development of R289, our dual IRAK1/4 inhibitor in a Phase 1b study in lower-risk MDS. Initial safety and efficacy data from that trial was published in an ASH abstract earlier this week, and we look forward to sharing additional data from a more recent data cut at the ASH meeting in December. Also at ASH, we will have additional data for olutasidenib; our strategic collaborations with MD Anderson and CONNECT are progressing well. These trials provide us with the opportunity to explore REZLIDHIA in a broad range of IDH1 mutant cancers in a cost- and time-efficient manner. Our first trial with MD Anderson evaluating REZLIDHIA in combination with two other agents in patients with Mutant IDH1 AML enrolled its first patient in September. Additionally, we continue to evaluate opportunities to in-license or acquire late-stage hematology and/or oncology assets to further expand our portfolio. In 2025, we will discuss our development plans for both R289 in lower-risk MDS and olutasidenib. Lastly, as we execute on our strategy to grow our business, we are doing so in a financially disciplined manner. Our strong commercial execution and cost-effective approach to clinical development has enabled us for the first time to generate positive third quarter and year-to-date net income. In summary, in the third quarter, we made significant progress in growing our business while achieving net income breakeven; we are well positioned to continue to drive value as we head into 2025. And with that, I'll turn the call over to Dave to provide a commercial update.

Thank you, Raul. We are very pleased with the strong growth in revenues in Q3. Moving to Slide 6, you see how our quarterly and annual sales have evolved since 2021. We have grown each quarter's sales over the previous year, and that growth continues particularly from last year to this year. We started the first quarter of 2023 with $23.8 million and are now reporting $38.9 million in the third quarter of 2024. That's an incremental 15.1 million, representing 63% growth in quarterly revenue over seven quarters. That growth has been driven by our strong commercial execution, in consistently building quarterly demand for TAVALISSE and driving broader awareness of REZLIDHIA through the first two years of its launch. The addition of GAVRETO and our ability to successfully transition it to our portfolio has also significantly expanded our top line. Compared to the third quarter of 2023, we generated 44% growth in the third quarter of 2024. As you can see, we're well on our way to delivering a record year of net product sales. Our commercial team is focused on execution, driving continued momentum for TAVALISSE, improving both institutional and community demand for REZLIDHIA, and successfully transitioning all GAVRETO patients and accounts to Rigel label products. My sincere thanks to the entire team for all their hard work to grow our business in 2024. Moving to Slide 7. I'll first discuss our performance with TAVALISSE in the third quarter. On Slide 8, you'll see our FDA-approved indication, which is for adult patients with chronic immune thrombocytopenia, or CITP, who've had an insufficient response to a previous treatment. Moving to Slide 9, I'm pleased to report another strong quarter for TAVALISSE with 2,797 bottles shipped to patients and clinics in the third quarter, a 16% increase versus the third quarter of 2023, and our eighth consecutive quarterly record high. We sold 2,793 bottles to our distribution network, resulting in $26.3 million in net product sales during the third quarter, an 8% increase from the same period last year. We continue to grow TAVALISSE demand, both through refills from patients who stay on the product and new prescriptions for patients who are trying TAVALISSE for the very first time. Moving to Slide 10. Now I'd like to take a few minutes to discuss our growing REZLIDHIA sales. On Slide 11, you'll see our FDA-approved indication for REZLIDHIA, which is for adult patients with relapsed or refractory acute myeloid leukemia with the susceptible IDH1 mutation as detected by an FDA-approved test. Moving to Slide 12, we shipped 444 bottles of REZLIDHIA to patients and clinics in Q3, more than doubling the demand generated in the same period a year ago. We sold 429 bottles of REZLIDHIA as our distribution channel reduced inventory by 15 bottles. This resulted in $5.5 million in third quarter net product sales, again, more than doubling compared to the prior year. We continue to stay focused on improving REZLIDHIA adoption, both in institutions and the community by raising awareness of REZLIDHIA's efficacy, particularly in patients who have failed upfront therapy with venetoclax. Moving to Slide 13. We are incredibly excited about our work to expand access to olutasidenib in markets outside the US. We're expanding our partnership with Kissei, who currently markets and distributes TAVALISSE in Japan to include a license agreement to develop and commercialize REZLIDHIA in Japan, Korea, and Taiwan. We believe Kissei is the right partner in these markets as we further our goal to make REZLIDHIA accessible globally, and we're continuing to explore other opportunities for partnerships outside the US to bring this beneficial product to AML patients in need in other markets around the globe. Moving to slide 14, I'll now discuss our third quarter performance for GAVRETO, the first full quarter in which GAVRETO was available through Rigel. On slide 15, I'll begin by reviewing the FDA approved indications for GAVRETO, which include the treatment of adult patients with metastatic RET fusion positive non-small cell lung cancer, as well as adult and pediatric patients 12 years of age and older, with advanced RET fusion positive thyroid cancer who require systemic therapy and who are radioactive iodine refractory. For the first full quarter with GAVRETO in our portfolio, we shipped 717 bottles to patients and clinics and sold 752 bottles of GAVRETO. Please note that GAVRETO is available in bottles of either 60 or 90 count capsules. For reporting purposes, we report the total number of 60 count equivalent bottles. This resulted in $7.1 million in GAVRETO third quarter net product sales. We have now sold a total of $9 million of GAVRETO since transitioning it in late Q2, and we are very happy that both the first full quarter of demand and net sales indicate that we are successfully transitioning GAVRETO patients, prescribers, and accounts to Rigel's distribution network. Moving to slide 17, I'd like to wrap up my comments with some early insights on what we saw during our first full quarter with GAVRETO. We are incredibly pleased with the progress we've made to ensure that current patients taking GAVRETO, as well as those newly prescribed, continue to have access without interruption. That prescribers can feel confident knowing that their patients can continue getting the therapy they need, based on the first full quarter shipping GAVRETO to patients and clinics. We have seen an exceptionally smooth transition of patients through our hub RIGEL ONECARE and the specialty pharmacies in our network. We have also seen solid ordering by many of the direct accounts. We had expected more orders through our specialty distributors. Our distributors have shipped 320 bottles to accounts representing about 45% of our business, while specialty pharmacies have shipped 397 bottles to patients, making up most of our business. We did expect that there would be more of our business coming through direct accounts and have noticed that a handful of expected top direct accounts still have not yet placed an order. Additionally, in the specialty pharmacy data, we are seeing that the majority of patients are prescribed GAVRETO below the standard dose of 400 milligrams once a day, indicating we may have an opportunity to reinforce dosing and administration, particularly the starting dose of GAVRETO. Overall, GAVRETO, REZLIDHIA, and TAVALISSE have all contributed to our strong year-over-year revenue growth, and we look forward to further expanding our impact on patients with our growing portfolio as we move forward to 2025. Thanks for your attention. I will now turn the call over to Lisa to discuss our development progress.

Thanks, Dave. Moving to slide 19. I'd like to begin by highlighting a series of abstracts that will be presented as posters at the upcoming ASH annual meeting in December. As Raul mentioned, initial data from the dose escalation part of our Phase 1b study of R289 in patients with relapsed or refractory lower-risk MDS will be presented during the poster session on Monday, December 9th. Updated results using a data cutoff date of October 25th will be shared at the meeting. Additionally, a number of presentations related to olutasidenib in patients with IDH1 mutated AML and MDS are planned. Moving to slide 20, we continue to execute on our strategy to expand our hematology and oncology pipeline. First, we're making meaningful progress advancing olutasidenib into new clinical indications alongside our partners MD Anderson and the Connect Cancer Consortium. We believe olutasidenib has potential in several cancers where mutated IDH1 plays a role, such as additional AML segments, myelodysplastic syndrome or MDS, and glioma, either as monotherapy or in combination. One clinical trial is now active under our MD Anderson collaboration. We're continuing to advance a lucid and glioma with CONNECT. R289 is our novel dual IRAK1-4 inhibitor that is currently being evaluated in a Phase 1B study in patients with relapsed or refractory lower-risk MDS. Enrollment in the fifth dose level is ongoing. We expect the DLT observation period will be completed within December. We also remain focused on evaluating potential opportunities to in-license or acquire products that would be a strategic fit for our portfolio. We're looking for differentiated products in hematology, oncology, or related areas—products that are late-stage, possibly with registrational data and more advanced, and products that can leverage our hematology and oncology infrastructure. As demonstrated with our acquisitions of olutasidenib and pralsetinib, our goal is to continue to find assets that align with our organization's pipeline and ability to execute. Slide 21 provides an overview of our strategic alliance with the MD Anderson Cancer Center to advance olutasidenib more broadly into AML, MDS, and beyond. We're very proud of this collaboration and have previously shared that in September, the first patient was enrolled in a Phase 1b/2 triplet therapy trial in IDH1 mutated AML evaluating olutasidenib, decitabine, and venetoclax. It is also planned to evaluate olutasidenib as a monotherapy in patients with IDH mutated CCUS and lower-risk MDS. The combination with an HMA in high-risk MDS, and as a post-transplant maintenance therapy for patients with IDH1 mutated hematologic malignancies. We expect these trials to position us to conduct subsequent registrational trial or trials. Moving to slide 22. Another important development collaboration we have is with the Connect Global Neuro-Oncology Consortium to conduct a Phase 2 trial in patients with IDH1 mutated high-grade glioma. Gliomas account for around 30% of CNS tumors in children, adolescents, and young adults. Approximately a third of these are high-grade gliomas translating to approximately 800 to 1000 new cases each year in the US. High-grade gliomas are a leading cause of cancer-related death in adolescents and young adults. Despite available therapies, the five-year survival of this population is less than 10%. Based on preliminary safety and efficacy results from a Phase 1B/2 clinical trial evaluating olutasidenib in heavily pretreated patients with relapsed or refractory IDH1 mutated glioma, we believe that olutasidenib has potential in glioma treatment. A Phase 2 study of olutasidenib in combination with temozolomide, called Target D, will be included as a treatment arm in CONNECT's target study, a molecularly guided phase 2 umbrella clinical trial for high-grade glioma. The goal of this study is to determine whether the combination of olutasidenib and temozolomide followed by olutasidenib monotherapy can prolong the progression-free survival of patients with IDH1 mutated high-grade glioma when given following radiotherapy. We, along with CONNECT, are excited about olutasidenib's potential to provide a much-needed new treatment option for this underserved patient population. We anticipate this trial will be activated by the end of this year. Next, I'd like to provide some background information on our clinical development program for lower-risk MDS with our novel dual IRAK1-4 inhibitor R289, which you will see on slide 23. Lower-risk MDS is an area of high unmet need in a primarily elderly patient population facing progressive cytopenias, particularly anemia resulting in transfusion dependency and increased risk of infections with a risk of progression to acute leukemia. The transfusion burden is high, with more than 80% of patients requiring red cell transfusions as supportive therapy. Long-term survival rates are poor due to transfusion burden and its associated morbidities, as well as a lack of curative therapies other than allogeneic stem cell transplantation, which a minority of patients are eligible for due to their advanced age and underlying health conditions. The primary goal of therapy is to reduce transfusion burden. Initial treatment options include ESAS if eligible and lenalidomide for del(5q) patients. For transfusion-dependent patients, there are no standard therapies for lower-risk MDS patients with recurrent or refractory disease. In fact, hypomethylating agents were approved about 20 years ago, underscoring the need for new safe and effective therapies for these patients. We believe that R289 has the potential to address the unmet needs in this patient population by targeting inflammatory signaling. Moving to slide 24, I'd like to highlight why we're excited about R289. Dysregulation of the immune and inflammatory signaling pathways is associated with MDS, with chronic stimulation of both the toll-like and IL-1 receptor pathways involving IRAK1 and IRAK4, leading to a pro-inflammatory marrow environment and cytopenias. IRAK1 and 4 activation independent of this pathway may also lead to persistent inhibition of hematopoietic cell differentiation. Co-targeting both IRAK1 and 4 may fully suppress inflammation and restore hematopoiesis in MDS. Clinically, IRAK4 inhibitors in MDS and AML have thus far only shown modest activity supporting this concept. In preclinical and healthy volunteer studies, R835, a dual IRAK1/4 inhibitor, was previously shown to suppress pro-inflammatory cytokine production. R289 is an oral pro-drug that is rapidly converted to R835 in the gut and is now being evaluated in lower-risk MDS. Slide 25 shows the design of our ongoing open-label Phase 1b study of R289 in patients with relapsed refractory lower-risk MDS, which has a dose escalation phase with a standard 3 plus 3 design and a dose expansion cohort for confirmatory safety. The primary endpoints for this trial are safety and selection of the recommended dose for expansion, and secondary endpoints include hematologic improvement response rates and pharmacokinetics. Based on emerging data from the study, we've recently included two additional cohorts with twice-daily dosing regimens for a total of five dose levels. The study continues to progress well, and enrollment in the fifth dose level, split dose of 500 milligrams and 250 milligrams daily, is nearing completion. We expect the DLT evaluation period of this dose level will be completed in December. We're encouraged by the preliminary safety and efficacy data from the study thus far in this elderly patient population with a high transfusion burden, as summarized in the recently published ASH abstract. Lastly, on slide 26. Our RIPK1 inhibitor programs are progressing well with our partner Lilly. RIPK1 is implicated in a broad range of inflammatory cellular processes and plays a key role in tumor necrosis factor signaling. Ocadusertib, our non-CNS penetrant RIPK1 inhibitor, previously referred to as R552, is currently being studied in an adaptive Phase 2a/2b clinical trial in up to 380 patients with active moderate to severe rheumatoid arthritis. Phase 2a enrollment of approximately 100 patients is advancing well, with preliminary analysis of the Phase 2a results anticipated within the first half of 2025. Our preclinical CNS penetrant RIPK1 inhibitor program is also progressing toward lead candidate nomination. We're excited about the progress of our programs and their broad potential in rheumatoid arthritis and other immune and CNS diseases. Now, I'll pass the call to Dean to discuss our financial results for the quarter.

Thank you, Lisa. I'm on slide number 28. During the third quarter, we shipped 2,793 bottles of TAVALISSE to our specialty distributors. 2,797 bottles of TAVALISSE were shipped to patients and clinics, while four bottles decreased the levels remaining in our distribution channels at the end of the quarter. We shipped 429 bottles of REZLIDHIA to our specialty distributors. 444 bottles of REZLIDHIA were shipped to patients and clinics, while 15 bottles decreased the levels remaining in our distribution channels at the end of the quarter. We shipped 752 bottles of GAVRETO to our specialty distributors; 717 bottles of GAVRETO were shipped to patients and clinics, while 35 bottles increased the levels remaining in their distribution channels at the end of the quarter. We reported net product sales from TAVALISSE of $26.3 million in the third quarter, a growth of 8% compared to $24.5 million in the same period in 2023. We reported net product sales of REZLIDHIA of $5.5 million in the third quarter, a growth of 107% compared to $2.7 million in the same period in 2023. Finally, we reported net product sales from GAVRETO of $7.1 million in the third quarter, the first full quarter of GAVRETO sales. Our net product sales from TAVALISSE, REZLIDHIA, and GAVRETO were recorded net of estimated discounts, chargebacks, rebates, returns, co-pay assistance, and other allowances of $17.4 million. For the third quarter of 2024, our gross to net adjustment for TAVALISSE, REZLIDHIA, and GAVRETO was approximately 36%, 22%, and 15% of gross product sales, respectively. We'd like to highlight that during the fourth quarter, we made certain changes to our distribution channel arrangements for TAVALISSE that will result in continued high-quality access, reduce our distribution costs, and favorably impact our gross-to-net adjustment in the future. While this change is not expected to impact our bottles shipped to patients and clinics during the quarter, we may see a reduction in bottles remaining in our distribution channels at the end of the quarter as inventories normalize. For the fourth quarter, we expect our gross to net adjustment for TAVALISSE, REZLIDHIA, and GAVRETO to be approximately 35%, 21%, and 22% of gross product sales, respectively. On the next slide. In addition to net product sales, our contract revenues from collaborations were $16.4 million in the third quarter. Contract revenues from collaborations consisted of $13 million from Kissei, $3.3 million from Grifols, and $100,000 from Medison. The $13 million in revenues from our Kissei collaboration includes $10 million related to an upfront fee from sublicensing REZLIDHIA and $3 million for the delivery of drug supplies. Moving on to costs and expenses, our cost of product sales was approximately $8 million for the third quarter of 2024. Total costs and expenses were $41.3 million, compared to $32.6 million in the same period for 2023. The increase in cost and expenses was primarily due to higher cost of product sales driven by increased product sales, a $2.3 million sublicensing revenue fee paid to Forma, increased royalties and amortization of intangible assets. In addition, there was an increase in personnel-related costs and commercial-related expenses. This quarter, we reported net income of $12.4 million, compared to a net loss of $5.7 million in the same period of 2023. We ended the quarter with cash, cash equivalents, and short-term investments of $61.1 million, up from $49.1 million. As of the end of the second quarter, we look to maintain our focused and disciplined financial approach into the future. With that, I'd like to turn the call back over to Raul.

Thank you, Dean. And moving on to slide 30, please, this is really an exciting time for Rigel. During the first three quarters of 2024, we delivered on our goals that we set earlier in the year. First, we generated strong growth in our commercial business. We've achieved another record demand quarter for TAVALISSE and REZLIDHIA and grew our net product sales year-over-year. We expanded our portfolio with the addition of GAVRETO, our third commercial product, which generated $7.1 million in net product sales in its first full quarter with us. We leveraged our commercial capabilities to transition the product to us and are now focused on maximizing its potential. And we're well on our way to deliver another record quarter of revenues for calendar year 2024. Second, we made significant advancements in our development pipeline. We continue to progress R289, and we are incredibly excited to present additional safety and efficacy data from our Phase 1b study in lower-risk MDS at the ASH meeting next month. Our strategic collaborations with MD Anderson and CONNECT continue to advance and we now have the first trial with MD Anderson underway. Lastly, as we made great strides in these areas, we continue to focus on maintaining financial discipline. All of these efforts have enabled us to generate positive net income for the three quarters year-to-date. Now on Slide 31 and as we think about the future for Rigel and our progress in 2024 and how it positions us to deliver continued growth in 2025 and beyond. Our corporate strategy remains focused on our major objectives, executing and expanding our commercial portfolio to generate top-line growth, advancing and growing our development pipeline, and operating in a financially disciplined manner. Becoming a profitable company will allow us to be self-sustaining and importantly to reinvest in our own development pipeline. We have made significant progress in 2024 and remain focused on continuing this momentum as we close out the year and head into 2025. Again, I'd like to thank you for your interest in Rigel. And with that, we will now open the call to your questions.

Thank you. Our first question comes from the line of Joe Pantginis with H.C. Wainwright. Please proceed with your question.

Hey, everybody. Good afternoon. Thanks for taking the questions. Nice to see the approved products progress. So, two questions if you don't mind. First, I was hoping to see if you can provide any more color with regard to TAVALISSE and the balance or mix between refills and new prescriptions.

Would you provide some commentary on that?

Sure. Thanks for the question, Joe. As you know, TAVALISSE is a product that patients take and will continue taking as long as their platelets are controlled and elevated, and you know sometimes that takes a while. So I will say that the majority of our business is carryover. Once we have patients on board, they will tend to stay on therapy, and that is the majority of our business. Because we've grown new patient starts over the last couple of years, I think we're seeing that growth and carryover go along with that. So, that's what I meant to say or that's what I was referring to when I said that both our growth is from new patients starting as well as carryover but the majority is carryover.

Got it. Appreciate that clarification and color. And then the second question I have, I want to make sure if I heard correctly. So, nice to see the early traction with GAVRETO. And if I heard you correctly, you said that several top centers have still not placed orders. I was just curious if this is really just based on logistics or how would you characterize it?

To clarify my earlier comments, there are a few key centers from which we have not received direct orders as expected. We are working to understand this situation. However, it's encouraging that a large portion of our data comes through the specialty pharmacy network. This might mean that patients are utilizing the specialty pharmacy network instead of having the institution purchase the drug directly. In my prepared remarks, I noted that 45% of our business was conducted through the distribution channel to direct accounts in the third quarter. As of October, this has improved to a 50-50 split. This indicates that our business is increasingly aligning with our expectations, with more transactions occurring through the direct channel. I hope this information helps, Joe.

It certainly does. Thanks for the color.

Thank you. Our next question comes from the line of Yigal Nochomovitz with Citi. Please proceed with your question.

Hi team. This is Ashiq on Yigal. Thanks for taking my question, and I appreciate all the updates here. I just had a follow-up on the last question on the GAVRETO for relaunch. How much of a stocking benefit was there in the initial phase of the launch at least with you guys? And on the sort of reported sales, seven million looks like it's at least on a similar run rate for the quarter compared to what the prior entity did with it last year. So how should we think about the growth trajectory from here? Should we be thinking about it in a more aggressive way or maybe more modestly from here given the restart?

Dave, you want to take that?

Sure. Thanks for the question. First of all, remember that at the end of Q2, right at the very end, we filled some orders to our distributors, and that was what I would refer to as stocking. It was about $1.9 million in sales. This quarter we sold 717 bottles or we shipped 717 bottles, and we had just a slight bit more than that in bottles sold. So there were another maybe 30-some bottles built up in the channel. The majority is demand that we saw in Q3 is true demand, patient demand, account demand. What I will say is that, obviously, we started the quarter with some level of shipments going out to patients and clinics. We ended the quarter with a much higher level of shipments going out to patients and clinics as more people transitioned over. So I can't really comment anymore than that, but we would expect to see some continued demand growth as we move forward.

And translated specifically into bottle counts. We had a 228 bottle increase in our distribution channel or inventory in Q2, which was essentially the full amount of revenue. Then we had an incremental build of inventory of 35 bottles. The remainder of the bottles in Q3 were from shipments to patients and clinics.

Understood. Thank you very much.

Thank you.

Thank you. Our next question comes from the line of Kalpit Patel with B. Riley Securities. Please proceed with your question.

Yes. Hi. Good afternoon. Thanks for taking the question. For the proof-of-concept data in lower-risk MDS, I guess, first, to the extent that you can share here, the Grade 3/4 adverse events that are listed in the abstract, was there any indication that these were dose-dependent or generally occurring in doses of 500 milligrams or higher?

Yes. Thanks for the question. I think that that will be shared in more detail in December at the ASH meeting.

At the ASH meeting in the poster presentation.

Right. Okay. Got it. And how much more data should we expect then at ASH in terms of maybe the number of patients and the number of cohorts and things like that?

Right. So for the abstract, we used a data cutoff date of July 15, and we're updating that to October 25. So, it's going to be about another three months of data. So you'll see data on the patients from the fourth dose level and a little bit beyond that.

Okay. Got it. Thank you very much.

Thank you, Kalpit.

Thank you. Our next question comes from the line of Farzin Haque with Jefferies. Please proceed with your question.

Hi. Good afternoon. Thank you for taking my question. To start off with R289 in the low-risk MDS patients, how should we think about the bar for success? And what would you need to see in Phase 1b to advance the program forward?

I'll let Lisa comment. Let me just preface this by saying that we're really excited about this data. This data—this molecule was discovered here at Rigel. We own full rights to it. We think definitely the most advanced IRAK1 and 4 inhibitor that there is available. We are excited to study it here in low-risk MDS, where we see a very good mechanism to indication. We're really interested to try here, and we're delighted to present the data that you saw in the abstract and substantially much more detail in the poster to come. In terms of the bar, Lisa, maybe you want to comment on that?

Yes. If we look at the treatment landscape in lower-risk MDS, obviously, we've got the first-line agents. Patients if they're eligible will have ESAs, followed by luspatercept. These are transfusion-dependent patients I'm talking about now and imetelstat. There's really nothing afterwards until HMAs, which has quite a gap. In terms of efficacy, HMAs in improving transfusion or reducing transfusion requirements have about a 20% transfusion independence associated with them, which is pretty low on one end. Our study is unique in that it's enrolling patients that have previously received HMAs, etc. I'd say, I would not put a number on it right now, but we're very encouraged by what we're seeing based on the preliminary safety and efficacy data so far.

That's helpful. And then for GAVRETO, I was just curious for the new safety signal related to the risk of severe and fatal infection, how rate limiting do you expect it to be for uptake? Does the competitive program have the same issue?

Lisa, do you want to comment on that?

I would say that from the clinical perspective, this really isn't a something new. Looking at the AERO study, we were aware that infections were reported. This is in the label already. We know that mechanistically there's a rationale for why this is happening. We know that in addition to RET inhibition, these increased risks of infections may stem from the off-target inhibition of JAK1 and JAK2, which are not the primary targets but nonetheless there is some off-target activity there. Most of the infections were pneumonias, which are very common in this patient population. About 80% of patients get pneumonia with lung cancer and receiving treatment for lung cancer. So this is a situation that oncologists are very familiar with managing.

If you want to comment on what you've heard from Simpson.

Sure. Patient safety is paramount and I'm very proud to say that we sent the DHCP to more than 10,000 healthcare providers, and we haven't received any calls to our medical information line regarding that update. As Lisa said, this is non-small cell lung cancer. These are oncologists who treat very sick patients all the time. You have two IRAK inhibitors on the market with significant warnings and precautions on both and with different sets of warnings and precautions. We don't see any—at this point, we don't see any changes in how we look at the opportunity for GAVRETO moving forward in the RET fusion-positive non-small cell cancer space.

That's helpful. Thank you so much.

Thank you. Our next question again comes from Kalpit Patel from B. Riley Securities. Please proceed with your question.

Yeah. Thanks for taking the follow-up. I just had one more on the lower MDS program. There was another agent Curis' IRAK inhibitor that was started in an investigator-sponsored study but then later withdrawn for the same indication. If you had to highlight a few differentiated factors with R289 versus the others, what would they be?

It's hard to comment on other people's studies. I would say ours is an IRAK1 and 4 inhibitor. I believe theirs was an IRAK4 inhibitor. That is a significant difference. I think Lisa highlighted in one of the slides where we showed that inhibiting both 1 and 4 provides a more profound inhibition of inflammatory cytokines presumably in the bone marrow in this case. So that is an important difference between those two. As I said earlier, I don't believe there's another IRAK1 and 4 inhibitor in development and certainly not in more advanced development available. We see this as the first to work on a 14 and that rationale is that more profound cytokine inhibition was one of the reasons we like 1 and 4 over 4. And Lisa, any other comments?

No, I think that pretty well summarizes it.

Okay. Wonderful. Thank you again.

Thank you, Kalpit.

Thank you. There are no further questions at this time. I would like to turn the floor back over to Mr. Raul Rodriguez for closing comments.

Thank you and thank you everyone for joining on the call today and your continued interest in Rigel. I can't say it's a very exciting time for the company having data to share and exciting product and more coming I think is really a great place to be. The year has gone very well for us in terms of commercial growth in addition to the portfolio and advancements in our development. We look forward to telling you more about that in 2025. So, with that, I'd like to also just always thank our employees for their continued commitment to our cause of improving the lives of patients and look forward to updating you further in other calls. Take care.

And this concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation.